{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:08:53Z","timestamp":1790662133220,"version":"4.1.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Overactive bladder (OAB) drugs are widely prescribed, yet the occurrence of atrial fibrillation (AF) after treatment initiation remains poorly characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated reports of AF associated with OAB medications using two spontaneous reporting systems (SRSs): the Japanese Adverse Drug Event Report (JADER) database and the U.S. FDA Adverse Event Reporting System (FAERS). We screened eight agents and assessed signals using three disproportionality metrics: the reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN). For drugs showing signals in both databases, we conducted stratified analyses by sex, age, and number of concomitant medications, and evaluated time-to-onset (TTO) using Weibull modeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Consistent AF signals were identified for solifenacin succinate and mirabegron, whereas other agents did not meet the prespecified criteria. Solifenacin met the criteria in women and older adults in both JADER and FAERS. Mirabegron met the criteria across multiple strata in both datasets, indicating cross-stratum reproducibility. TTO was right\u2010skewed, with most reports occurring within one year of initiation. Exploratory Weibull modeling, based on limited numbers of date\u2010complete reports, suggested a wear-out pattern for solifenacin in JADER and an early pattern in FAERS, while mirabegron showed a random pattern in JADER and an early pattern in FAERS. These failure\u2010type patterns should therefore be interpreted cautiously.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings are hypothesis-generating, given the limitations of SRSs, such as underreporting, missing dates, and unknown exposure\u2014and they reflect reporting patterns rather than causal risk. They outline strata and early treatment periods that may warrant clinical attention and help prioritize pharmacovigilance and targeted hypothesis\u2010driven evaluation in routine OAB care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1700587","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:34:12Z","timestamp":1767854052000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Atrial fibrillation signals associated with overactive bladder drugs across JADER and FAERS: disproportionality and time-to-onset analyses"],"prefix":"10.3389","volume":"16","author":[{"given":"Kyosuke","family":"Nagura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Sagara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2042098620938595","DOI":"10.1177\/2042098620938595","article-title":"Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future","volume":"11","author":"Alomar","year":"2020","journal-title":"Ther. Adv. Drug Saf."},{"key":"B2","volume-title":"VESIcare (","year":"2022"},{"key":"B3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf."},{"key":"B5","doi-asserted-by":"publisher","first-page":"100674","DOI":"10.1016\/j.curtheres.2022.100674","article-title":"Selectivity and maximum response of vibegron and mirabegron for \u03b23-adrenergic receptors","volume":"96","author":"Brucker","year":"2022","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"B6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40264-015-0289-5","article-title":"Comparison of statistical signal detection methods within and across spontaneous reporting databases","volume":"38","author":"Candore","year":"2015","journal-title":"Drug Saf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a \u03b2(3)-adrenoceptor agonist, in overactive bladder","volume":"63","author":"Chapple","year":"2013","journal-title":"Eur. Urol."},{"key":"B8","volume-title":"Practical aspects of signal detection in pharmacovigilance: report of CIOMS Working Group VIII","year":"2010"},{"key":"B9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jamda.2019.10.022","article-title":"Adverse outcomes of polypharmacy in older people: systematic review of reviews","volume":"21","author":"Davies","year":"2020","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"B10","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/pds.3622","article-title":"Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database","volume":"23","author":"de Boissieu","year":"2014","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1001\/jamaneurol.2015.2161","article-title":"Association between atrial fibrillation and dementia in the general population","volume":"72","author":"de Bruijn","year":"2015","journal-title":"JAMA Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/clc.22667","article-title":"Silent atrial fibrillation: epidemiology, diagnosis, and clinical impact","volume":"40","author":"Dilaveris","year":"2017","journal-title":"Clin. Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1483591","DOI":"10.3389\/fcvm.2024.1483591","article-title":"QTc interval prolongation and risk of atrial fibrillation recurrence: a meta-analysis and observational cohort study","volume":"11","author":"Ding","year":"2024","journal-title":"Front. Cardiovasc. Med."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.15332\/s2027-3355.2018.0001.03","article-title":"Comparison of confidence intervals obtained by normal approximation and bootstrap for the Weibull distribution\u2019s parameters","author":"Estad\u00edstica","year":"2018","journal-title":"Comunicaciones Estad\u00edstica"},{"key":"B15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B16","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1136\/heartjnl-2021-320417","article-title":"Smartphone detection of atrial fibrillation using photoplethysmography: a systematic review and meta-analysis","volume":"108","author":"Gill","year":"2022","journal-title":"Heart"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/pds.5108","article-title":"Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese adverse drug event report database","volume":"29","author":"Hasegawa","year":"2020","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"B20","first-page":"20","article-title":"Spontaneous reporting in pharmacovigilance: strengths, weaknesses and recent methods of analysis","volume":"1","author":"Kasliwal","year":"2012","journal-title":"J. Clin. Prev. Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/eurheartj\/17.suppl_c.48","article-title":"Follow-up of atrial fibrillation: the initial experience of the Canadian registry of atrial fibrillation","volume":"17","author":"Kerr","year":"1996","journal-title":"Eur. Heart J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.12997\/jla.2023.12.2.96","article-title":"Risk stratification of cardiovascular disease according to age groups in new prevention guidelines: a review","volume":"12","author":"Kim","year":"2023","journal-title":"J. Lipid Atheroscler."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1485190","DOI":"10.3389\/fphar.2024.1485190","article-title":"A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1516449","DOI":"10.3389\/fphar.2025.1516449","article-title":"Safety evaluation of Irinotecan: a real-world disproportionality analysis using FAERS and JADER databases during 2004\u20132024","volume":"16","author":"Lou","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00228-017-2359-3","article-title":"Comparison of cardiovascular events among treatments for overactive bladder: a Danish nationwide cohort study","volume":"74","author":"Margulis","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? A systematic review of definitions","volume":"17","author":"Masnoon","year":"2017","journal-title":"BMC Geriatr."},{"key":"B27","unstructured":"NDB open data site\n          \n          \n          2025"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1111\/bph.13897","article-title":"The \u03b23-adrenoceptor agonist mirabegron increases human atrial force through \u03b21-adrenoceptors: an indirect mechanism?","volume":"174","author":"Mo","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1248\/bpb.b17-00561","article-title":"Evaluation of drug-induced photosensitivity using the Japanese adverse drug event report (JADER) database","volume":"40","author":"Nakao","year":"2017","journal-title":"Biol. Pharm. Bull."},{"key":"B30","volume-title":"PASS sample size software: confidence intervals for the Weibull shape parameter","author":"NCSS","year":"2022"},{"key":"B31","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1111\/ijcp.12433","article-title":"Safety and tolerability of the \u03b23-adrenoceptor agonist mirabegron for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomized Phase III trials and of a 1-year randomized Phase III trial","volume":"68","author":"Nitti","year":"2014","journal-title":"Int. J. Clin. Pract."},{"key":"B32","doi-asserted-by":"publisher","first-page":"i4482","DOI":"10.1136\/bmj.i4482","article-title":"Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis","volume":"354","author":"Odutayo","year":"2016","journal-title":"BMJ"},{"key":"B33","doi-asserted-by":"publisher","first-page":"515","DOI":"10.4236\/pp.2018.912040","article-title":"Onset time profiles for syncope associated with \u03b11-adrenoceptor blockers in males: analysis of a spontaneous adverse drug event database","volume":"9","author":"Ohyama","year":"2018","journal-title":"Pharmacol. Pharm."},{"key":"B34","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0167-9473(99)00114-0","article-title":"Bayesian neural networks with confidence estimations applied to data mining","volume":"34","author":"Orre","year":"2000","journal-title":"Comput. Stat. Data Anal."},{"key":"B35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3904\/kjim.2023.521","article-title":"Screening and diagnosis of atrial fibrillation using wearable devices","volume":"40","author":"Park","year":"2025","journal-title":"Korean J. Intern. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1901183","article-title":"Large-scale assessment of a smartwatch to identify atrial fibrillation","volume":"381","author":"Perez","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B37","unstructured":"Japanese adverse drug event report (JADER) database\n          \n          \n          2015"},{"key":"B38","unstructured":"Vesicare\u00ae tablets 2.5 mg, 5 mg [package insert]\n          \n          \n          2023"},{"key":"B39","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.eururo.2015.09.007","article-title":"Cardiovascular safety of \u03b23-adrenoceptor agonists for the treatment of patients with overactive bladder syndrome","volume":"69","author":"Rosa","year":"2016","journal-title":"Eur. Urol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s40264-020-00957-w","article-title":"Risk factor considerations in statistical signal detection: using subgroup disproportionality to uncover risk groups for adverse drug reactions in VigiBase","volume":"43","author":"Sandberg","year":"2020","journal-title":"Drug Saf."},{"key":"B42","doi-asserted-by":"publisher","first-page":"195","DOI":"10.26599\/TST.2018.9010074","article-title":"Parallel ADR detection based on spark and BCPNN","volume":"24","author":"Sun","year":"2019","journal-title":"Tsinghua Sci. Technol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1001\/jamainternmed.2019.2011","article-title":"Association of mirabegron with the risk of arrhythmia in adult patients 66 years or older: a population-based cohort study","volume":"179","author":"Tadrous","year":"2019","journal-title":"JAMA Intern. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1177\/0962280212462295","article-title":"Comparison of two drug safety signals in a pharmacovigilance data mining framework","volume":"25","author":"Tubert-Bitter","year":"2016","journal-title":"Stat. Methods Med. Res."},{"key":"B45","unstructured":"About VigiBase\n          \n          \n          2025"},{"key":"B46","doi-asserted-by":"crossref","unstructured":"FDA adverse event reporting system (FAERS) database\n          \n          \n          2024","DOI":"10.2139\/ssrn.4583117"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.jacc.2004.08.053","article-title":"Drug-induced atrial fibrillation","volume":"44","author":"van der Hooft","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B49","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/B978-0-12-817728-0.00072-3","article-title":"Sex differences in drug-induced QT prolongation","volume-title":"Sex and cardiac electrophysiology","author":"Vicente","year":"2020"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1376535","DOI":"10.3389\/fphar.2024.1376535","article-title":"Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00192-024-06029-2","article-title":"Global prevalence of overactive bladder: a systematic review and meta-analysis","volume":"36","author":"Zhang","year":"2025","journal-title":"Int. Urogynecol. J."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1700587\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:34:18Z","timestamp":1767854058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1700587\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":51,"alternative-id":["10.3389\/fphar.2025.1700587"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1700587","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"article-number":"1700587"}}